EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting RSK2 reverses endocrine resistance in ER-positive breast cancer via inhibiting the c-Myc–ERBB4 signaling pathway

Ting Jiang, Shilong Jiang, Yueying Cheng, Xiaohui Yu, Zonglin Chen, Hang Li, Shijun Cao, Zhongyuan Xiang, Ruigang Zhao, Wenjun Yi, Jinming Yang, Yan Cheng

Acta Pharmaceutica Sinica B · 2026-11 · 16 (11) · 7344-7362

DOI: 10.1016/j.apsb.2026.05.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-11. Verfasst von Ting Jiang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Pharmaceutical Association, Hunan Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endocrine therapy remains a major adjuvant treatment for estrogen receptor (ER)-positive breast cancer, yet its clinical efficacy is frequently compromised by primary or acquired resistance, leading to tumor recurrence and poor prognosis. In this study, we identified RSK2 (p90 ribosomal S6 kinase 2) as a critical mediator of endocrine resistance in ER-positive breast cancer. Analysis of publicly available datasets and our clinical samples revealed that high expression of RSK2 is associated with unfavorable outcomes in patients treated with endocrine therapy. RSK2 overexpression confers resistance to both tamoxifen and fulvestrant, two commonly used ER antagonists. We show that RSK2 is upregulated in tamoxifen-resistant breast cancer cells compared to parental controls, and that RSK2 knockdown restores tamoxifen sensitivity and inhibits tumor progression in vitro and in vivo. Further, we found that RSK2 stabilizes c-Myc by phosphorylating it at serine 62, thereby enhancing the transcriptional of ERBB4, which in turn promotes ER-driven proliferation. Moreover, ‌positive correlations between RSK2, c-Myc and ERBB4‌ were observed in ER-positive breast cancer specimens from patients. Notably, by screening the FDA-approved drug library, we identified emetine, an anti-protozoan drug used in the treatment of ameobiasis, as a potential RSK2 degrader and a modulator of tamoxifen resistance in preclinical models. Together, these findings establish the RSK2-c-Myc-ERBB4 axis as a therapeutic vulnerability in endocrine resistant breast cancer, and propose the repurposing of emetine as a sensitizer of endocrine therapy for breast cancer.

Schlagwörter

Stichwörter der Autor:innen

ER-Positive breast cancerERBB4EmetineEndocrine resistancePhosphorylationRSK2Tamoxifenc-Myc

Autor:innen und Institutionen

  • Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha 410011, China.
  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China.
  • Human Cancer Hospital, Changsha 410013, China.
  • Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • Department of Laboratory Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, China.

Förderung

  • National Natural Science Foundation of China
  • Chinese Pharmaceutical Association
  • Hunan Provincial Natural Science Foundation
  • China Postdoctoral Science Foundation

Zitieren

APA

Jiang, T., Jiang, S., Cheng, Y., Yu, X., Chen, Z., Li, H., Cao, S., Xiang, Z., Zhao, R., Yi, W., Yang, J., & Cheng, Y. (2026). Targeting RSK2 reverses endocrine resistance in ER-positive breast cancer via inhibiting the c-Myc–ERBB4 signaling pathway. Acta Pharmaceutica Sinica B, 16(11), 7344-7362. https://doi.org/10.1016/j.apsb.2026.05.001

Vancouver

Jiang T, Jiang S, Cheng Y, Yu X, Chen Z, Li H, et al. Targeting RSK2 reverses endocrine resistance in ER-positive breast cancer via inhibiting the c-Myc–ERBB4 signaling pathway. Acta Pharmaceutica Sinica B. 2026;16(11):7344-7362. doi:10.1016/j.apsb.2026.05.001

BibTeX
@article{Jiang2026,
  author = {Jiang, Ting and Jiang, Shilong and Cheng, Yueying and Yu, Xiaohui and Chen, Zonglin and Li, Hang and Cao, Shijun and Xiang, Zhongyuan and Zhao, Ruigang and Yi, Wenjun and Yang, Jinming and Cheng, Yan},
  title = {Targeting RSK2 reverses endocrine resistance in ER-positive breast cancer via inhibiting the c-Myc–ERBB4 signaling pathway},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {7344--7362},
  doi = {10.1016/j.apsb.2026.05.001}
}
Kostenlos starten →